Correlation Between Nuvalent and Oncolytics Biotech

Can any of the company-specific risk be diversified away by investing in both Nuvalent and Oncolytics Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvalent and Oncolytics Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvalent and Oncolytics Biotech, you can compare the effects of market volatilities on Nuvalent and Oncolytics Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvalent with a short position of Oncolytics Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvalent and Oncolytics Biotech.

Diversification Opportunities for Nuvalent and Oncolytics Biotech

0.31

Correlation Coefficient

Nuvalent  Oncolytics Biotech

Weak diversification

The 3 months correlation between Nuvalent and Oncolytics is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Nuvalent and Oncolytics Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncolytics Biotech and Nuvalent is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvalent are associated (or correlated) with Oncolytics Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncolytics Biotech has no effect on the direction of Nuvalent i.e., Nuvalent and Oncolytics Biotech go up and down completely randomly.

Pair Corralation between Nuvalent and Oncolytics Biotech

Given the investment horizon of 90 days Nuvalent is expected to generate 0.75 times more return on investment than Oncolytics Biotech. However, Nuvalent is 1.33 times less risky than Oncolytics Biotech. It trades about 0.07 of its potential returns per unit of risk. Oncolytics Biotech is currently generating about -0.01 per unit of risk. If you would invest  5,974  in Nuvalent on August 13, 2024 and sell it today you would earn a total of  3,568  from holding Nuvalent or generate 59.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Nuvalent  vs.  Oncolytics Biotech

Nuvalent

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Nuvalent are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Nuvalent disclosed solid returns over the last few months and may actually be approaching a breakup point.

Oncolytics Biotech

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Oncolytics Biotech showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Nuvalent and Oncolytics Biotech

The main advantage of trading using opposite Nuvalent and Oncolytics Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvalent position performs unexpectedly, Oncolytics Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will offset losses from the drop in Oncolytics Biotech's long position.

The idea behind Nuvalent and Oncolytics Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.